Novartis top|line results for CANOPY|1 Phase III study support ...

Novartis top-line results for CANOPY-1 Phase III study support ...

Novartis announced today that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall survival (OS) and ...

Novartis provides update on Phase III CANOPY-A study evaluating ...

Novartis launched the CANOPY study program after observing significantly lower than expected rates of lung cancer mortality among patients in ...

Results From the CANOPY-1 Trial | Journal of Clinical Oncology

Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Results From ...

Novartis top-line results for CANOPY-1 Phase III study support ...

Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer. Novartis Pharma AG. 25 October 2021 11 min read ...

canopy-1 - Cancer Trial Results

P3, N=245; CANOPY-2 (NCT03626545); Sponsor: Novartis Pharmaceuticals; "Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885)...

Novartis provides update on Phase III study evaluating ...

Basel, March 9, 2021 — Novartis announced today the Phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta ...

Top-line results for Novartis CANOPY-1 Phase III study support ...

Top-line results for Novartis CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer. Posted on October 26, 2021. Novartis ...

Novartis top-line results for CANOPY-1 Phase III study support ...

Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer · NASDAQ Market News · The U.S. Market for ...

Repositioning canakinumab for non-small cell lung cancer ... - NCBI

1. Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer | Novartis n.d. https ...

Novartis lung cancer drug fails another Phase III trial - Reuters

"CANOPY-1 provides critical insights into the treatment of this devastating disease, and we will continue to analyse the data and conclusions, ...

Results From the CANOPY-A Double-Blind, Randomized Clinical Trial

CANOPY-A did not show a DFS benefit of adding canakinumab after surgery and adjuvant cisplatin-based chemotherapy in patients with resected, stage II-III NSCLC.

Novartis Top-line Results for CANOPY-1 Phase III Study Support ...

Novartis AG. (10/25/21). "Press Release: Novartis Top-line Results for CANOPY-1 Phase III Study Support further Evaluation of Canakinumab in ...

News Archive | Novartis

October 2021. Key Release Oct 25, 2021. Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer.

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful ...

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial · EAST HANOVER ...

Novartis' Canakinumab Flunks Another Phase III NSCLC Trial

Novartis released results from the Phase III CANOPY-A trial, showing ... “These positive signals supported the study of canakinumab as adjuvant ...

Novartis provides update on Phase III study evaluating ...

• The CANOPY clinical trial program is designed to help answer critical questions about the role of interleukin-1 beta (IL-1β) in pro-tumor ...

Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in ...

GlobeNewswire 2022 - Novartis provides update on Phase III CANOPY-A study evaluating canakinumab as adjuvant treatment in non-small cell lung cancer open_in_new.

Novartis investigational iptacopan Phase III study demonstrates ...

Basel, October 2, 2023 — Novartis today announced positive top-line results ... Phase III APPLAUSE-IgAN study (NCT04578834) at 9 months1.

Clinical trial results database

The Purpose of CTRD application is to increase the transparency of Novartis Interventional Clinical Trials in innovative medicines. The trial results are ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or ...

1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III ...